Connect with us

International

The Veil Of Silence Over Excess Deaths

The Veil Of Silence Over Excess Deaths

Authored by Sonia Elijah via the Brownstone Institute,

Around the world, there has been a deafening…

Published

on

The Veil Of Silence Over Excess Deaths

Authored by Sonia Elijah via the Brownstone Institute,

Around the world, there has been a deafening silence over excess deaths from governments and the mainstream media, who not so long ago were quite fixated on the daily death toll for Covid. 

On October 20th, a 30-minute adjourned debate (20 rejections later) on excess deaths in the UK House of Commons was finally secured by Andrew Bridgen, MP for North West Leicestershire and member of the Reclaim Party. 

Bridgen began his speech to the sound of erupting cheers from the full, upper public gallery, in stark contrast to the almost empty chamber below. 

Where were the hundreds of MPs who would normally sit shoulder to shoulder in the chamber? It appears, an increase in deaths of their constituents was not a pressing issue for them on that Friday afternoon. 

We’ve experienced more excess deaths since July 2021 than in the whole of 2020, unlike the pandemic, however, these deaths are not disproportionately of the old, in other words, the excess deaths are striking down people in the prime of life but no-one seems to care. I fear history will not judge this house kindly. 

Strikingly, excess deaths have been seen across all age groups, which Bridgen pointed out during his speech.

The graph below shows the pooled weekly total number of deaths for all ages, from 27 participating countries: Austria, Belgium, Cyprus, Denmark, Estonia, Finland, France, Germany, Germany (Berlin), Germany (Hesse), Greece, Hungary, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland, UK (England), UK (Northern Ireland), UK (Scotland), and UK (Wales).

Source: EUROMOMO

According to the British Medical Journal, ‘Excess deaths are calculated as the difference between current numbers of deaths and those in a baseline year, and the excess can differ depending on the baseline and methodology used.’ 

This important point on how excess can differ depending on the baseline used, was raised by Bridgen.

ONS Manipulating the Data, Again

Bridgen explained:

‘To understand if there is an ‘excess’ by definition, you need to estimate how many deaths would have been expected. The Organisation for Economic Co-operation and Development (OECD) used 2015-2019 as a baseline…Unforgivably, the UK ONS (Office for National Statistics) have included deaths in 2021, as part of their baseline calculation for expected deaths- as if there was anything normal about the deaths in 2021- by exaggerating the number of deaths expected, the number of excess deaths can be minimized. 

Why would the ONS want do that?

My early 2022 interview with Norman Fenton, professor of Risk Information Management at Queen Mary, University of London, revealed how the ONS had also been manipulating the data on deaths involving Covid-19 by vaccination status. 

Fenton coauthored a paper analysing the ONS report: ‘Deaths involving COVID-19 by vaccination status, England: deaths occurring between 2 January and 24 September 2021.’ 

The paper concluded that the ONS was guilty of ‘systematic miscategorisation of vaccine status’ and that the COVID-19 vaccines did not reduce all-cause mortality, but rather produced genuine spikes in all-cause mortality shortly after vaccination.

The Backlog of Unregistered Deaths

Bridgen went on to highlight a critical failure in how data on deaths are being collected.

‘There is a total failure to collect (never mind publish) data on deaths that are referred for investigation to the coroner. Why does this matter? A referral means that it can be many months and given the backlog, many years, before a death is formally registered. Needing to investigate a cause of death is fair enough. Failing to record when the death happened, is not. Because of this problem, we actually have no idea how many people died in 2021, even now. The problem is greatest for the younger age groups, where a higher proportion of deaths are investigatedThis data failure is unacceptable.’

Excess Deaths in the Younger Age Groups

My investigative report into child deaths following Pfizer/BioNTech mRNA vaccine revealed there was an increase in deaths in the 0-14 age group, around the time the mRNA vaccine was authorised in children, 12-15 years of age.

Source: EUROMOMO

Bridgen drew attention to the fact that in a judicial review on a decision to vaccinate younger children, the ONS shockingly refused in court to give anonymised details (which they admitted was statistically significant) on the increase in excess deaths observed in the second half of 2021, for young adolescent males. Bridgen made the point that potentially even more excess deaths would have been observed, if those referred to the coroner had been included.

Excess Deaths Observed in Heavily Vaccinated Countries

In August 2023, fifteen EU Member States that recorded excess deaths, the highest rates were observed in Ireland (21.1 percent), Malta (16.9 percent), Portugal (12.7 percent) and the Netherlands (9.4 percent), according to Eurostat. It should be noted that, as of January 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. 

Increase in Cardiac Arrests

Bridgen, brought attention to the fact that Dr Clare Craig, diagnostic pathologist and co-chair of HART, was the first to highlight the increase in cardiac arrest calls after the vaccine rollout in May 2021.

Bridgen stated:

‘Ambulance data for England provides another clue. Ambulance calls for life-threatening emergencies were running at a steady 2,000 calls per day until the vaccine rollout. From then they rose to 2,500 daily, and  calls have stayed at that level since.’

Source: NHS Key statistics: England, July 2023

Category 1: An immediate response to a life-threatening condition, such as cardiac or respiratory arrest. 

The Anomalies of the Pfizer Clinical Trial

Bridgen shared the fact that:

Four participants in the vaccine group of the Pfizer trial died from cardiac arrest compared to only one in the placebo group. Overall there were 21 deaths in the vaccine group up to March 2021, compared to 17 in the placebo group. There were serious anomalies about the reporting of deaths in this trial, with the deaths in the vaccine group taking much longer to report than those in the placebo group. That is highly suggestive of a significant bias in what was supposed to be a blinded trial.

An Israeli study clearly showed an increase in cardiac hospital attendances among 18-39 year olds that correlated with vaccination not covid. 

Australia, the Perfect Control Group

Bridgen explained that Australia had almost no covid when vaccines were introduced making it the perfect control group. 

The state of South Australia had only had 1,000 cases of covid in total across the whole population by December 2021, before omicron arrived. What was the impact of vaccination there? For 15-44 year olds, there were historically around 1,300 emergency cardiac presentations a month. With the vaccine roll-out to the under 50s, this rocketed reaching 2,172 cases in November 2021 in this age group alone, which was 67% more than usual.

Overall there were 17,900 South Australians who had a cardiac emergency in 2021 compared to 13,250 in 2018, a 35% increase. The vaccine must clearly be the No.1 suspect in this, and it cannot be dismissed as a coincidence. Australian mortality has increased from early 2021 and that increase is due to cardiac deaths.

How the Regulators Have Failed

The regulators also missed the fact that in the Pfizer trial the vaccine was made for the trial participants in a highly controlled environment, in stark contrast to the manufacturing process used for the public – which was based on completely different technology. Just over 200 participants were given the same product that was given to the public, but not only was the data from these people never compared to those in the trial for efficacy and safety, but the MHRA has admitted that it dropped the requirement to provide this data. That means there was never a trial on the Pfizer product actually rolled out to the public, and that product has never even been compared to the product that was actually trialled.

The vaccine mass production processes use vats of Escherichia Coli and presents a risk of contamination with DNA from the bacteria, as well as bacterial cell walls, which can cause dangerous reactions. This is not theoretical; there is now sound evidence that has been replicated by several labs across the world that the mRNA vaccines were contaminated by significant amounts of DNA which far exceeded the usual permissible levels. Given that this DNA is enclosed in a lipid nanoparticle delivery system, it is arguable that even the permissible levels would have been too high. These lipid nanoparticles are known to enter every organ of the body. As well as this potentially causing some of the acute adverse reactions that have been seen, there is a serious risk of this foreign bacterial DNA inserting itself into human DNA. Will anyone investigate? No they won’t.

The BBC’s Role

How ironic that the BBC has chosen to remain utterly silent on the issue of excess deaths, despite its ardent daily coverage of the Covid death toll. 

In regards to vaccine injuries, the BBC took a far more proactive role. The public broadcaster took it upon itself to collaborate with Facebook to take down the online pages of Covid-19 vaccine injury groups, by drawing attention to the fact that these groups used carrot emojis to circumvent Big Tech censors. 

Many viewers of Bridgen’s speech took to social media to draw attention to the fact that the BBC also took it upon itself to plaster the debate with its own captions, in an attempt to contradict what the MP was saying. 

One caption read: The NHS says COVID-19 vaccines used in the UK are safe and the best protection from getting seriously ill with the disease.

What is interesting is that Bridgen did not mention vaccines and autism during his debate but this did not stop the BBC from inserting the caption below.

‘NHS guidance states vaccines do not cause autism, there is no evidence of a link between MMR vaccine and autism.’

It must be noted that the BBC helms the Trusted News Initiative (an alliance of Big Tech and the mainstream media) set up in 2019 to combat ‘anti-vax misinformation’ in real-time. Therefore, its collaboration with Facebook to censor stories on vaccine harms; the lack of any coverage on excess deaths and the more recent captioning of Bridgen’s speech – shows just how effectively it has executed that role. 

In Conclusion

Bridgen closed the debate by stating the following:

The experimental covid-19 vaccines are not safe and are not effective. Despite there being only limited interest in the Chamber from colleagues—I am very grateful to those who have attended—we can see from the Public Gallery that there is considerable public interest. I implore all Members of the House, those who are present and those who are not, to support calls for a three-hour debate on this important issue. Mr Deputy Speaker, this might be the first debate on excess deaths in our Parliament—indeed, it might be the first debate on excess deaths in the world—but, very sadly, I promise you it will not be the last.

Republshed from the author’s Substack

Sonia Elijah has a background in Economics. She’s a former BBC researcher and now works as an investigative journalist.

Tyler Durden Mon, 10/30/2023 - 02:00

Read More

Continue Reading

International

Gates-backed PhIII study tuberculosis vaccine study gets underway

A large study of an experimental vaccine for the world’s biggest infectious disease has finally kicked off in South Africa.
The Bill & Melinda Gates…

Published

on

A large study of an experimental vaccine for the world’s biggest infectious disease has finally kicked off in South Africa.

The Bill & Melinda Gates Medical Research Institute (MRI) will test a tuberculosis vaccine’s ability to prevent latent infections from causing potentially deadly lung disease. Last summer the nonprofit said it would foot $400 million of the estimated $550 million cost of running the 20,000-person Phase III trial.

It’s a pivotal moment for a vaccine whose origins date back 25 years when scientists identified two proteins that triggered strong immunity to the bacterium that causes tuberculosis. A fusion of those proteins, paired with the tree bark-derived adjuvant that helps power GSK’s shingles shot, comprise the so-called M72 vaccine.

Thomas Scriba

After decades of failures in the field, the vaccine impressed scientists in 2018 when GSK found that it was 54% efficacious at preventing lung disease in a 3,600-person Phase IIb study.

But the Big Pharma decided that a full-blown trial was too expensive to conduct on its own. Gates MRI stepped in to license the vaccine in early 2020, right before the Covid pandemic shifted global vaccine priorities towards the coronavirus, further stalling the tuberculosis shot.

“There’s been frustration that it’s taken so long to get this trial up and running,” Thomas Scriba, deputy director of immunology for the South African Tuberculosis Vaccine Initiative, told Endpoints News last summer.

At last, the vaccine is getting a chance to prove itself in a bigger study. If successful, it could lead to the first new shot for tuberculosis in over a century.

Emilio Emini, CEO of the Gates MRI, told Endpoints that the initial results may come in roughly four to six years. “Hopefully this will galvanize a refocus on TB,” he said. “It’s been ignored for many, many years. We can’t ignore it anymore.”

A substantial impact

Even though an existing vaccine helps protect babies and children against severe tuberculosis, the bacterium responsible for the disease still causes roughly 10 million new cases and 500,000 deaths each year.

Emilio Emini

By vaccinating adolescents and adults who test positive for infections but don’t have symptoms of lung disease, the Gates MRI hopes the shot will help prevent mild infections from becoming severe ones, curtail transmission of the bug, which is predominantly driven by people with lung disease, and reduce deaths.

“The impact would be substantial,” Emini said. But he cautioned that the biology behind mild and severe diseases is still mysterious. “The reality is that no one really knows what keeps it under control.”

The study, which will take place at 60 sites across seven countries, will include some people who are not infected with tuberculosis to ensure that the vaccine is safe in that broader population.

“Having to pre-test everybody is not going to make the vaccine easy to deliver,” Emini said. If the vaccine is ultimately approved, it will likely be used in targeted communities with high tuberculosis, rather than across a whole country, he added. “In practice, you would immunize everybody in those populations.”

Emini described the Gates MRI’s rights to the vaccine as “close to a worldwide license.” GSK retained rights to commercialize the vaccine in certain countries but declined to specify which ones.

A spokesperson for GSK said that the company “has around 30 assets under development specifically for global health … none of which are expected to generate significant return on investment.”

“It is not sustainable or practical in the longer term for GSK to deliver all of these alone. So we continue to work on M72, but in partnership with others,” the spokesperson added.

If the shot works, Emini said that the Gates MRI will sublicense it to a manufacturer that will be responsible for making and marketing the vaccine. The details are still being worked out, he noted.

Read More

Continue Reading

Government

Greenback Surges after BOJ Hikes and Ends YCC and RBA Delivers a Dovish Hold

Overview: The US dollar is surging today against
most of the G10 currencies, and although the intraday momentum is stretched
ahead of start of the North…

Published

on

Overview: The US dollar is surging today against most of the G10 currencies, and although the intraday momentum is stretched ahead of start of the North American session, there may be little incentive to resist before the end of the FOMC meeting tomorrow. The Bank of Japan's rate hike and the end of Yield Curve Control were not seen as the start of the tightening cycle. The two-year JGB yield slipped to a two-week low and settled below its 20-day moving average for the first time since mid-January. The Reserve Bank of Australia delivered a dovish hold by dropping the reference the future tightening. The yen (~-0.95%) and Australian dollar (~-0.85%) are the weakest of the G10 currencies. Emerging market currencies are lower, led by the Philippine peso (~-0.65%). The offshore yuan is weaker for the sixth consecutive session. 

Japanese, Australian, and New Zealand equities bucked the regional trend to advance today. Stoxx 600 in Europe is slightly lower, and if sustained, it would be the fourth consecutive losing session. That would be the long losing streak since last October. US index futures are nursing small losses. Ten-year JGB and Australian bond yield fell almost three basis points today. European benchmark yields are mostly slightly softer, though the periphery is lagging the core today. The US 10-year yield is little changed near 4.32%. The high for the year is near 4.35%. The US two-year yield did set a new high for the year yesterday near 4.75%. It is near 4.72% now. The greenback's strength is capping gold, which is trading inside yesterday's range and straddling the $2150 area. May WTI soared to $82.50 yesterday as its recent rally was extended amid Ukrainian strikes on Russian refiners. Diesel futures rose for the fourth consecutive session yesterday and gasoline futures extend its rally for a sixth session. May WTI is consolidating in a narrow range around $82. 

Asia Pacific

The Japanese press reports turned out to be fairly accurate: the Bank of Japan hiked its overnight target rate to 0%-0.1%. It scrapped the Yield Curve Control and confirmed it would stop buying ETFs. The one surprise was that the central bank indicated it would continue to purchase long-term bonds as needed. Governor Ueda, on one hand, said that the sustained 2% inflation target is not in hand, which sounded dovish. He also recognized that if the positive trends for wages and prices lift inflation expectations, and higher prices results, rate hikes may be necessary. The 10-year yield softened by almost three basis points (to ~0.73%). The Nikkei rallied 1%, and the yen was sold. The US dollar reached about JPY150.50.

As widely expected, the Reserve Bank of Australia left its cash target rate at 4.35%, where it has been since it was lifted by 25 bp last November. Economic activity has slowed, and price pressures are moderating, but the RBA seems to be in no hurry to unwind the November hike. Still, it dropped the reference to possible future hikes. The dovish hold sent the Australian dollar to a nine-day low near $0.6510. The futures market is not 100% confident the RBA will do so before September. However, the odds of an August cut have been marked up to around 97% from about 78% yesterday. 

The dollar is rising against the Japanese yen for the sixth consecutive session. It matches the longest advancing streak since last August and lifted the greenback to two-week highs near JPY150.70. The greenback approached JPY151 in mid-February through early March. The high from 2022 and 2023 was closer to JPY152. The intraday momentum indicators are stretched ahead of the North American open, but there may be little incentive to resist before tomorrow's FOMC meeting. What is being seen as a dovish hold by the RBA has sent the Australian dollar to nearly $0.6500. The trendline off the mid-February and early March lows comes in today a little below there. The low earlier this month was set slightly below $0.6480. The intraday momentum indicators are stretched. Initial resistance now is seen int he $0.6520-25 area. The greenback's gains, especially against the yen, have weighed on the Chinese yuan. The dollar is challenged the CNY7.20 cap that has not been violated this year. The PBOC set the dollar's reference rate at CNY7.0985 (CNY7.0943 yesterday). The Bloomberg average was CNY7.2020 (CNY7.1993 yesterday). The dollar is rising against the offshore yuan for the sixth consecutive session. It has reached CNH7.2130, its highest level in two weeks. The high for the year was set on February 14 near CNH7.2335.

Europe

The focus will not shift to Europe until Thursday. Three central banks meet then, Norway's Norges Bank, the Swiss National Bank, and the Bank of England. It is true the UK sees February CPI tomorrow. The year-over-year rate is expected to fall toward 3.5% from 4.0% and the core rate is seen falling to 4.6% from 5.1%. The UK's three-month annualized rate may near 2% and the six-month annualized increase maybe around 1.6%. Still, the market does not expect the BOE or the other west European central banks to change policy. Still, we suspect the risk is for a SNB move to get ahead of the ECB. The macro backdrop is conducive for a move with softer growth and low inflation. 

The March ZEW survey in Germany showed a little improvement. The assessment of the current situation remains poor. It edged up to -80.5 from -81.7. At its worst, during the pandemic, it fell to -93.5 in May 2020. It had recovered and peaked at 21.6 in October 2021, and had already begun weakening again before Russia's invasion of Ukraine. It was at -10.2 in January 2022. The expectations component is a different story. It rose for the eighth consecutive month to 31.7, which is the highest reading since February 2022. The high last year was set in February at 28.1.

The euro met sellers in the US morning yesterday as it pushed above $1.09. The selling knocked it down to new session lows near $1.0865 It has been sold to $1.0835 today, around where the (50%) retracement of the rally from the February 14 lows and the 200-day moving average are found. A break of this area targets $1.08. Note that in the futures market, the non-commercial (speculative) net long euro position has risen by 50% since the mid-February low through March 12 that is covered by the most recent CFTC report. Meanwhile, the non-commercial net long sterling position has risen every week this year but one, and at nearly 70.5k contracts (GBP62.5k per contract or almost $5.6 bln position), it is the largest net long position since 2007. Sterling extended its losses yesterday to nearly $1.2715, and has been sold to almost $1.2665 today, the lowest level since March 4. The $1.2670 area corresponds to the (61.8%) retracement of the recovery off the year's low set on February 14 near $1.2535. The intraday momentum indicators are stretched, but there is little chart support ahead of $1.2600.

America

The focus, of course, is on tomorrow's Fed meeting. No one expects the Fed to do anything. It is more about what the Fed says, and here, the dot plot is important. Keen interest is in the number of rates cuts the median dot signals. Three cuts were signaled in December. While CPI and PPI were slightly above market expectations, we do not think that they deviated much from what the Fed anticipated. To us, a key consideration is Fed Chair Powell's acknowledgement that officials did not need to see better data to boost their confidence that inflation was headed back to target. It just needed to see good data. Other macro forecasts may be tweaked. The 4.1% unemployment rate anticipated for this year looks low. It was at 3.9% in February. The median dot was for the headline and core PCE deflator to be at 2.4% at the end of the year. They stood at 2.4% and 2.8%, respectively in January and are expected to be unchanged when the February series is reported next week. The median dot in December was for the economy to grow 1.4% this year. The median forecast in Bloomberg's monthly survey was for 2.1% growth, which is the same as the IMF's projection. On tap today, February housing starts and permits, which are expected to tick up after weather-related weakness in January.

Canada reports February CPI today. Given the base effect, the 0.6% median forecast in Bloomberg's survey translates into a 3.1% year-over-year rate. It was at 2.9% in January. The low print in 2023 was in June at 2.8%. The underlying core measures are expected to be flat. The swaps market has about a 50% chance of a cut in June. It nearly fully discounted on March 5, the day before the Bank of Canada met. The summary of its deliberations will be published tomorrow. The market has about 60 bp of cuts discounted for this year, which is two quarter-point moves and around a 40% chance of a third. A 100 bp of cuts was fully discounted as recently as February 20.

The US dollar hovered around little changed levels against the Canadian dollar yesterday. Neither rising US equities (risk-on) nor an extension of oil's rally did much for the Canadian dollar. Resistance near CAD1.3550 has been overcome today and it the greenback looks poised to re-test the CAD1.36 area that capped the greenback in late February and earlier this month. A band of resistance extends toward CAD1.3620-25. Yesterday, the US dollar rose for the third consecutive session against the Mexican peso, which matches the longest advance in six months. The nearly 0.9% rally was the most since mid-January. Mexico was on holiday yesterday and the thin markets may have exacerbated the move. The US dollar rose to a six-day high of almost MXN16.87. This effectively recouped nearly half of the greenback's losses this month. Today, the dollar is approaching the next retracement (61.8%) and the 20-day moving average are near MXN16.93. Brazil was not closed and fell for the third consecutive session. In fact, the dollar poked above BRL5.03, its highest level since last November 1. Nearly all emerging market currencies fell yesterday. The South African rand (~-0.95%) was the weakest followed by the Mexican peso (~0.75%). Emerging market currencies are no match for the dollar's surge today. The MSCI Emerging Market Currency Index is off for the fifth consecutive session. 


Disclaimer 

Read More

Continue Reading

International

Anti-Semitism As The Harbinger Of Global Chaos

Anti-Semitism As The Harbinger Of Global Chaos

Authored by Stephen Soukup via American Greatness,

On the off chance you hadn’t noticed,…

Published

on

Anti-Semitism As The Harbinger Of Global Chaos

Authored by Stephen Soukup via American Greatness,

On the off chance you hadn’t noticed, the world appears to be at an especially precarious moment presently. Obviously, war continues to rage in Ukraine and Gaza, with no end in sight to either conflict. Great Britain and Japan are currently in recession. Canada’s economy is an absolute disaster, with almost no hope of near-term recovery. Much of continental Europe and China are struggling economically, if not officially contracting. Some experts believe that the global economy more generally is sliding, slowly but surely, into recession. The only economic bright spot in the world is the United States, and even here we have our problems with consumer spending and sentiment, massive credit concerns, and inarguably sticky inflation.

Meanwhile, China is investing in and winning friends, and influencing people in the Global South. U.S.-backed Kurdish leaders are warning that ISIS is resurgent in Syria and Iraq. The Marine general in charge of U.S. Africa Command is warning of Russia’s increasing influence on that continent. Sudan remains mired in civil war. Nigeria is plagued by Islamist terrorism and mass kidnappings. Mexico is in the midst of a full-blown war with the drug cartels, who continue to grow bolder and more militarily sophisticated.

Everywhere one looks, chaos reigns—or, at the very least, bubbles just below the surface.

Perhaps most telling among the signs of disarray is the unnerving rise of antisemitism in the United States, Europe, and throughout the world. Antisemitism, in general, has been intensifying, slowly but surely, over the last decade or so. Over the last few months, however, it has emerged fully into the open, undaunted and unembarrassed. What was once considered shameful and disconcerting is now warmly welcomed as a “rational” response to American foreign policy, Israeli war practices, “colonialism,” and “white privilege.”

All of this is troubling, to put it mildly, both in and of itself and as a harbinger of greater and more deadly global unrest.

Hatred of and anger toward Jews is not the same as other forms of bigotry.  

In many ways, the history of Western anti-Jewish hatred mirrors the history of Western political chaos and collapse.  Or, to put it another way, historically, Jews are not only the perennial scapegoats during periods of social upheaval and displacement, but resurgent anti-Semitism serves as the proverbial canary in the coal mine for the rise of revolutionary movements.

In his classic, The Pursuit of the Millennium, the British historian Norman Cohn argues that the Jewish diaspora generally fit comfortably, if tentatively into European society for most of the first thousand years or so A.D., and only became a hated and perpetually persecuted minority with the rise of utopian Millenarianism that accompanied and then outlived the Crusades.  Beginning then and continuing for the next nearly a thousand years, Europeans came to associate Jews with the antichrist and thus to associate hatred and persecution of Jews with preparing the battlespace for the Second Coming.  Many historians, including Hannah Arendt, believed that the anti-Semitism that was such an integral part of the West’s 20th-century collapse into totalitarianism was relatively new and, in any case, distinct from medieval anti-Semitism.  Cohn’s history suggests otherwise, connecting the religious eschatology of medieval Europe to the quasi-religious eschatology of post-Enlightenment Europe, thereby connecting the persistence of Western anti-Semitism as well.

Cohn tells us that millenarian moments and the millenarian movements that capitalize on those moments all share a common group of characteristics. They all appear under certain social and economic conditions. They all appeal to a certain segment of the population at large, who then present themselves as economic, spiritual, and political leaders. They all utilize scapegoats, meaning that they all identify a different, usually much smaller segment of the population on whom they can blame all the world’s ills and then set about to cure those ills through the elimination of the scapegoat. And more often than not, that scapegoat tends to be Jewish.

In the conclusion to the second edition of Pursuit of the Millennium, Cohn notes that the millenarian fervor of the middle ages may have changed, but it never really died, and it maintained its common characteristics even as it became secular or “quasi-religious.” He wrote:

The story told in Pursuit of the Millennium ended some four centuries ago but is not without relevance to our own times. [I have] shown in another work [Warrant for Genocide: The Myth of the Jewish World Conspiracy and the Protocols of the Elders of Zion] how closely the Nazi phantasy of a world-wide Jewish conspiracy of destruction is related to the phantasies that inspired Emico of Leningrad and the Master of Hungary; and how mass disorientation and insecurity have fostered the demonization of the Jew in this as in much earlier centuries. The parallels and indeed the continuity are incontestable.

The parallels between the rise of Nazism and the current global unrest and demonization of the Jewish people are also largely incontestable. The election that brought Hitler to power didn’t happen in a vacuum, after all. It happened in the midst of global chaos, namely the Great Depression. It also followed the decadence and distortion of the Weimer Era. As the New York Fed has shown, even a global pandemic—the 1919 Spanish Flu outbreak—contributed to the sense of discomfort and disconnect among the German population, prompting increased support for Hitler and his Nazis.

The present global chaos doesn’t have to end the same way the chaos of a century ago did. It doesn’t have to result in the ascension of millenarian ideologies and their totalitarian defenders. History has shown that extremism can be short-circuited and radical ideologies undone. The first step in doing so, however, must be to bring an end to the rationalization of the persecution of the world’s Jews. The second step is to end the persecution itself.

Antisemitism is ugly and shameful, and it must be treated as such. For their sake and ours.

Tyler Durden Tue, 03/19/2024 - 02:00

Read More

Continue Reading

Trending